Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$18.56 USD
+0.10 (0.54%)
Updated May 31, 2024 04:00 PM ET
After-Market: $18.59 +0.03 (0.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Denali Therapeutics Inc. [DNLI]
Reports for Purchase
Showing records 101 - 120 ( 184 total )
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
All About ALS at DNLI Webinar - Continue to Hold Favorable View on Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Denali?s ALS/FTD Webinar Showcases its Small Molecule Programs?Key Takeaways
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Investor Day Takeaways, Read Throughs
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Positive DNL310 Interim Data - A Means For Invigorating the TV Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biomarker >> Clinical Outcomes?? Didn''t Make Sense To Us Either
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Unexpected AAIC Plenary Session Helps Provide Clarity on Denali NfL Riddle
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Breaking Down Barriers With TV; DNL310 Data Continues To Look Impressive
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Superior Efficacy and Consistent Safety Profile Differentiates DNL310 - Pipeline Implications; Reit Buy; Raise PT to $105
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Consistent CSF Target Engagement Data Might Establish Pipeline Potential Across Multiple Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A